Patent disclosure requirements for therapeutic antibody patents

被引:2
作者
De Luca, Carmela [1 ,2 ]
Trifonova, Anastassia [1 ,2 ]
机构
[1] Bereskin & Parr LLP, Life Sci Grp, Montreal, PQ, Canada
[2] Bereskin & Parr LLP, Life Sci Grp, Toronto, ON, Canada
关键词
Therapeutic antibodies; disclosure requirements; patent protection; support requirements; sufficiency; Canada; United States and United Kingdom;
D O I
10.1080/13543776.2017.1296950
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Introduction: Therapeutic antibodies have grown to become an important product class within the biopharmaceutical market. A prerequisite to their commercialization is adequate patent protection. Disclosure requirements and the types of claims available in different jurisdictions can impact the scope of protection available for antibodies. Areas covered: A comparative review of statutory bases, patent office practices and selected decisions in Canada, the United States and the United Kingdom related to disclosure requirements is provided. Expert opinion: Differences in disclosure requirements exist in different jurisdictions which can impact the type of claims obtained and their survival when attacked in litigation. Including a wide variety of claim types is a key strategy to ensuring therapeutic antibodies are adequately protected. Method of use claims may provide advantages and broader protection in some circumstances and should also be considered.
引用
收藏
页码:867 / 875
页数:9
相关论文
共 31 条
[1]  
[Anonymous], 2016, European Patent Register, Patent No. 1994937
[2]  
[Anonymous], 2013, EX GUID PAT APPL REL
[3]  
[Anonymous], 2013, LEV DISCL REQ ANT
[4]  
[Anonymous], 2016, GUID PROT YOUR PAT A
[5]  
[Anonymous], 2010, Re Immunex Corp Patent App No 583,988, Patent No. 583988
[6]  
[Anonymous], 2016, [Re Chugai Seiyaku and Kabushiki Kaisha, Patent App. No 2,451,493], Patent No. 2451493
[7]  
[Anonymous], [Re The New York Blood Center Inc, Patent App. No 2,308,623, CD 1323(PAB)], Patent No. 2308623
[8]  
[Anonymous], 1991, AS KAS KOG KK S APPL
[9]  
[Anonymous], 2014, COST DEV WIN MARKET
[10]  
Charles A, 2001, Immunobiology: The Immune System in Health and Disease, V5th